Skip to content

Tribute Pharmaceuticals Canada Inc.: financial reference

Explore Tribute Pharmaceuticals Canada Inc. financial histories from SEC filings, with original units, reporting periods, filing dates and downloadable source data.

Filing record ends 2015-03-03

The latest filing in this captured record is a 10-K filed 2015-03-03. No later filing is in the SEC companyfacts record captured on 2026-09-22. Tribute Pharmaceuticals Canada Inc. may have stopped filing, merged, or changed its reporting entity; nothing on this page describes its current status. Values are as reported at the time.

Reported financial histories

Choose a measure to inspect its definition, complete selected history and filing provenance. Each row shows the latest period available for that selected concept and original unit. Separate currencies and reporting intervals remain separate rows. Coverage dates can differ between concepts. A recent capture does not imply recent accounting coverage; these amounts are not prices.

Latest periods by selected concept and original unit
MeasurePeriod startPeriod endValueUnitFiled
Total assets-2014-12-3153,079,740CAD2015-03-03
Total assets-2011-12-3119,208,435USD2012-04-03
Total liabilities-2014-12-3122,739,009CAD2015-03-03
Total liabilities-2011-12-315,835,574USD2012-04-03
Stockholders equity-2014-12-3130,340,731CAD2015-03-03
Stockholders equity-2011-12-3113,372,861USD2012-04-03
Cash and cash equivalents-2014-12-313,505,791CAD2015-03-03
Cash and cash equivalents-2011-12-312,227,973USD2012-04-03
Net income or loss2014-01-012014-12-31-5,606,942CAD2015-03-03
Net income or loss2011-01-012011-12-31-521,781USD2012-04-03
Operating cash flow2014-01-012014-12-31-1,888,085CAD2015-03-03
Operating cash flow2011-01-012011-12-31-1,011,448USD2012-04-03
Capital expenditure payments2014-01-012014-12-3112,759CAD2015-03-03
Capital expenditure payments2011-01-012011-12-319,990USD2012-04-03
Revenue2014-01-012014-12-3116,871,792CAD2015-03-03
Revenue2011-01-012011-12-313,869,881USD2012-04-03
Financing cash flow2014-01-012014-12-3135,946,434CAD2015-03-03
Financing cash flow2011-01-012011-12-31-24,243USD2012-04-03
Investing cash flow2014-01-012014-12-31-32,586,574CAD2015-03-03
Investing cash flow2011-01-012011-12-31-1,088,621USD2012-04-03
Retained earnings or deficit-2014-12-31-19,902,853CAD2015-03-03
Retained earnings or deficit-2011-12-31-4,374,590USD2012-04-03
Basic weighted-average shares2014-01-012014-12-3171,940,005shares2015-03-03
Diluted weighted-average shares2014-01-012014-12-3171,940,005shares2015-03-03
Basic earnings per share2014-01-012014-12-31-0.08CAD/shares2015-03-03
Basic earnings per share2011-01-012011-12-31-0.02USD/shares2012-04-03
Diluted earnings per share2014-01-012014-12-31-0.08CAD/shares2015-03-03
Diluted earnings per share2011-01-012011-12-31-0.02USD/shares2012-04-03
Net property, plant and equipment-2014-12-311,012,285CAD2015-03-03
Net property, plant and equipment-2011-12-311,207,462USD2012-04-03
Share-based compensation expense2014-01-012014-12-31426,715CAD2015-03-03
Share-based compensation expense2011-01-012011-12-31332,532USD2012-04-03
Current assets-2014-12-317,150,347CAD2015-03-03
Current assets-2011-12-314,182,488USD2012-04-03
Interest expense2014-01-012014-12-311,441,729CAD2015-03-03
Current liabilities-2014-12-318,771,516CAD2015-03-03
Current liabilities-2011-12-314,311,374USD2012-04-03
Goodwill carrying amount-2014-12-313,599,077CAD2015-03-03
Goodwill carrying amount-2011-12-313,408,741USD2012-04-03
Net finite-lived intangible assets-2014-12-3140,540,150CAD2015-03-03
Net current accounts receivable-2014-12-312,145,319CAD2015-03-03
Net current accounts receivable-2011-12-31763,810USD2012-04-03
Operating expenses2014-01-012014-12-3111,660,875CAD2015-03-03
Operating expenses2011-01-012011-12-313,112,691USD2012-04-03
Net inventory-2014-12-311,037,387CAD2015-03-03
Net inventory-2011-12-31870,630USD2012-04-03
Gross profit2014-01-012014-12-319,129,075CAD2015-03-03
Gross profit2011-01-012011-12-312,426,529USD2012-04-03
Selling, general and administrative expense2014-01-012014-12-3110,149,854CAD2015-03-03
Selling, general and administrative expense2011-01-012011-12-313,034,740USD2012-04-03
Additional paid-in capital-2014-12-312,713,605CAD2015-03-03
Additional paid-in capital-2011-12-3117,747,451USD2012-04-03
Long-term debt-2014-12-31290,700CAD2015-03-03
Gross property, plant and equipment-2014-12-312,154,674CAD2015-03-03
Accumulated depreciation on property, plant and equipment-2014-12-311,142,389CAD2015-03-03
Net intangible assets excluding goodwill-2014-12-3140,958,870CAD2015-03-03
Net intangible assets excluding goodwill-2011-12-3110,409,744USD2012-04-03
Prepaid expenses and other current assets-2014-12-31187,279CAD2015-03-03
Prepaid expenses and other current assets-2011-12-31124,101USD2012-04-03
Comprehensive income or loss2014-01-012014-12-31-5,606,942CAD2015-03-03
Net income available to common stockholders2014-01-012014-12-31-5,606,942CAD2015-03-03
Amortization of intangible assets2014-01-012014-12-311,332,118CAD2015-03-03
Change in accounts receivable2014-01-012014-12-31-1,553,553CAD2015-03-03
Change in inventories2014-01-012014-12-317,444CAD2015-03-03

Filings

19 Tribute Pharmaceuticals Canada filings with published measures: what each annual or quarterly report tagged, with the periods it covered, as reported in that filing. The histories above show the latest-filed value per period.

Inspect the source

Entity
Tribute Pharmaceuticals Canada Inc. / CIK 0001159019
Captured
SEC response SHA-256
580713a84aa79c7c06f7641b783696cf8e0676bb71dd55f93cd67e6d441393a2

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Latest-filed annual-report facts per unit and reporting period at capture time. Duration facts cover 300 to 400 days. This selection can include restatements and is not a point-in-time backtest dataset. Missing concepts are omitted, never zero-filled. Values retain original units and are not currency converted. Extended concepts require compatible unit shapes and at least three reporting ends with changing values within one unit. Constant or incompatible added histories are omitted.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0001159019.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))